• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis posts Q2 beat, promises to hold off on drug price hikes

July 18, 2018 By Sarah Faulkner

NovartisShares in Novartis (NYSE:NVS) were up today after the company beat expectations on Wall Street with its second-quarter financial results.

The Switzerland-based company posted profits of $7.77 billion, or $3.34 per share, on sales of $13.16 billion for the three months ended June 30. Novartis saw its quarterly sales climb 7% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.29, ahead of consensus on The Street, where analysts were looking for sales of $12.94 billion.

“We made significant progress this quarter to transform Novartis into a focused medicines company.  We completed the Alcon strategic review, exited the OTC joint venture, and strengthened our innovation engine with the acquisition of AveXis,” CEO Vas Narasimhan said in prepared remarks.

The chief executive also told reporters at Bloomberg and CNN that Novartis plans to hold off on raising the prices of any of its medicines for the remainder of the year. The move comes a week after President Donald Trump criticized Pfizer and its CEO, Ian Read, on Twitter about the company’s plan to hike the prices of several of its drugs.

Read eventually agreed to defer any price increases until next year and Trump swiftly followed his critical tweet with a call to action for other pharmaceutical companies.

“Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same,” he tweeted.

Novartis’ plan to hold off on its price hikes comes as the company works to find a way out of the limelight – reports revealed in May that former Novartis CEO Joe Jimenez agreed to pay nearly $1.2 million to a consulting firm linked to Michael Cohen, the president’s attorney.

The pharmaceutical company said that it paid $100,000 per month for a one-year deal to gain Cohen’s insight on how to navigate the Trump administration’s approach to healthcare policy, bringing the total to more than $1 million.

Novartis has fought to distance itself from the controversy, largely pinning the decision to enter into the contract with Cohen on ex-CEO Jimenez. The company has also noted that it quickly determined that Cohen could not deliver the insight that Novartis was looking for.

Today’s Q2 beat and promise to hold off on drug price increases helped push the company’s shares up – NVS shares were trading at $80.86 apiece in mid-morning activity, up 2.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Novartis

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS